Introducing Roger Mora de la Serna DC9
My PhD goals: Our mission is to develop better models of cystinosis, study the underlying cellular and molecular pathways, and assess novel viral vector-based gene therapies in isogenic cell and organoid models of cystinosis. In addition, my aim in joining a PhD network is to learn from brilliant scientists around Europe and develop a collaborative mindset where we can contribute to impactful research that ultimately can benefit patients’ quality of life.
My Background: I was born and raised in Barcelona, Spain, where I studied for a BSc in nanoscience and nanotechnology, focusing my senior year on nanomedicine. I graduated in 2023, and I joined the Erasmus Mundus Joint Master’s Degree (EMJMD) in Precision Medicine, studying at the Université Grenoble Alpes, the University of Naples Federico II, and performing my Master’s thesis at the University of Cambridge. Aiming to keep on researching novel applications of nanomedicine in an international environment, I joined ORGESTRA MCSA PhD Network to work on viral vectors for cystinosis gene therapy.
My research interests: Since my BSc degree, I have been captivated by all the potential that nanomedicine can offer in bringing novel therapies to the clinic. My main area of interest is to contribute to the length of the preclinic development: from a fundamental understanding of the disease to creating better models and testing novel therapeutic approaches.
My hobbies: I like to keep a balanced lifestyle: reading, meeting with friends, travelling and doing sport. I used to play water polo, and I have kept on with water-related sports. In addition, I enjoy playing chess, so if you are up for a chess game, just let me know!
Master thesis: Bioactive Protein-based Nanoparticles for Cancer Therapy
Cancer continues to be a growing threat to human health. The side effects and lack of guaranteed efficacy of classical chemotherapy treatments have moved biomedical research towards more specific therapies. Nanomedicine has garnered considerable attention in recent decades due to its numerous advantages in drug delivery and targeting. Historically, biologically inert nanocarriers such as liposomes, polymeric or albumin nanoparticles (NPs) have been preferred for in vivo applications. By contrast, the innovative approach hereby uses NPs composed of biologically active proteins, which can synergistically perform their natural functions and simultaneously release pharmaceutical ingredients. Two active proteins were selected for cancer treatment applications to construct the nanoparticles. Firstly, novel cytochrome c-based nanocarriers (@CytC and @CytC:HSA) that can incorporate different drugs and synergistically kill cancer and senescent cells. And secondly, biocompatible myoglobin-based nanoparticles (@Mb and @Mb:HSA) capable of being loaded with drugs and release oxygen in hypoxic tumor microenvironment conditions.